Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Joyce O’Shaughnessy, Sherko Kümmel et al.|New England Journal of Medicine|2020Cited by 3.1k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortés, Gallardo Carlos, David W. Cescon et al.|The Lancet|2020Cited by 1.8k